1.3200 +0.03 (2.33%)
After hours: 7:55PM EDT
Commodity Channel Index
|Bid||1.2800 x 4000|
|Ask||1.3200 x 4000|
|Day's Range||1.2648 - 1.3400|
|52 Week Range||0.7000 - 3.0200|
|Beta (5Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.80|
AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it does not intend to revise further its offer under the terms of its previously announced agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) (NASDAQ: TTPH), and it expects the agreement to be terminated by Tetraphase. On June 1, 2020, Tetraphase disclosed that its board of directors had determined that an amended proposal from Melinta Therapeutics, Inc. constituted a "Superior Offer" under the terms of the AcelRx Merger Agreement. Under the terms of the agreement, in connection with a termination of the merger agreement, AcelRx will be paid a break-up fee of approximately $1.8 million.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the Jeffries Virtual Healthcare Conference to be held June 2 at 1:30 p.m. ET (10:30 a.m. PT). A live webcast link of the event can be found on the Company's website at http://ir.acelrx.com/upcoming-events. Management will also be hosting one-on-one investor meetings throughout the day.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of an amendment to its merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) (NASDAQ: TTPH), with revised consideration of $37.0 million in stock and cash based on the AcelRx closing share price on May 28, 2020, plus up to $16.0 million in contingent value rights (CVRs) payable in cash.
With me today are Vince Angotti, our Chief Executive Officer; and Dr. Pam Palmer, our Chief Medical Officer. Also, on the call with us today is Dr. Christian Tvetenstrand, who is the Chairman of Surgery and Director of Trauma at Wilson Medical Center, the United Health Services Hospital, who will share his experience with DSUVIA.
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -33.33% and -85.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2020 financial results.
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) and Novartis AG (NYSE: NVS) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir obtained full regulatory approval in Japan.Moderna Inc (NASDAQ: MRNA) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273.The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences * Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 * American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 * 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 * Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca. The sNDA seeks approval of Rubraca as a monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.Clinical Readouts ASGCT Conference Presentations Abeona Therapeutics Inc (NASDAQ: ABEO) is due to present updated interim results from the Transpher A and Transpher B studies, Phase 1/2 trials of ABO-102 and ABO-101, respectively, in mucopolysaccharidosis type IIIA, aka as Sanfilippo syndrome type.Rocket Pharmaceuticals Inc (NASDAQ: RCKT will present updated data from Phase 1/2 FANCOLEN-I study, which is evaluating the safety and efficacy of infusion of autologous CD34 + cells transduced with a lentiviral vector carrying the FANCA gene in patients with Fanconi anemia subtype A, and updates from the Phase 1 LAD-I study that is evaluating its investigational gene therapy RP-L201 to treat severe Leukocyte Adhesion Deficiency-I.Avrobio Inc (NASDAQ: AVRO) is scheduled to make an oral presentation on new data from the Phase 2 trial of AVR-RD-01 for Fabry (Wednesday). The company will also make an oral presentation of new data from the collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 in cystinosis. Another oral presentation on new data from a preclinical research program for a gene therapy for Pompe disease is also scheduled for Wednesday.Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is due to present updated data from the first three cohorts of a Phase 1/2 study of DTX301 in treating ornithine transcarbamylase deficiency (Wednesday). The company will also present updated data from the confirmatory cohort from a Phase 1/2 study of DTX401 in glycogen storage disease Type 1a (Friday).View more earnings on IBBPfizer Inc. (NYSE: PFE) will present Phase 1b data for PF-06939926 in Duchenne muscular dystrophy on Friday.Krystal Biotech Inc (NASDAQ: KRYS) will present a poster on KB407, an HSV-1 based gene therapy vector, for the treatment of cystic fibrosis.See Also: Gilead Works To 'Maximize Global Supply' Of Coronavirus Candidate Remdesivir Amid Threat Of Patent LossOther Readouts Genocea Biosciences Inc (NASDAQ: GNCA) will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 - Genocea's neoantigen cell therapy. (Tuesday)Krystal Biotech is due to present at the SID meeting with results from a Phase 1/2 study of in vivo gene therapy KB105 for treating autosomal recessive congenital ichthyosis as well as results of a Phase 1/2 trial that is evaluating in vivo correction of dystrophic epidermolysis bullosa by direct cutaneous COL7A1 gene replacement.Caladrius Biosciences Inc (NASDAQ: CLBS) will present at the SCAI meeting Thursday with full data from the ESCaPE-CMD study of CLBS16 for the treatment of coronary microvascular dysfunction.Constellation Pharmaceuticals Inc (NASDAQ: CNST) said abstracts of a presentation due at the June 11-14 European Hematology Association meeting will be made available Thursday. The abstract pertains to an interim update from the MANIFEST Phase 2 study that is evaluating CPI-0610 in myelofibrosis.Auris Medical Holding Ltd (NASDAQ: EARS) is due to release top-line data in early May from the Phase 1b trial that is evaluating AM-201 in healthy volunteers. AM-201 is the company's investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.Earnings Monday * Amneal Pharmaceuticals Inc (NYSE: AMRX) (before the market open) * Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) * Apyx Medical Corp (NASDAQ: APYX) (before the market open) * Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open) * bluebird bio Inc (NASDAQ: BLUE) (before the market open) * Sesen Bio Inc (NASDAQ: SESN) (before the market open) * Mylan NV (NASDAQ: MYL) (before the market open) * Zimmer Biomet Holdings Inc (NYSE: ZBH) (before the market open) * Wave Life Sciences Ltd (NASDAQ: WVE) (before the market open) * Passage Bio Inc (NASDAQ: PASG) (before the market open) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) (before the market open) * Oyster Point Pharma Inc (NASDAQ: OYST) (before the market open) * Recro Pharma Inc (NASDAQ: REPH) (before the market open) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) (before the market open) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) (before the market open) * Assertio Therapeutics Inc (NASDAQ: ASRT) (before the market open) * Eagle Pharmaceuticals Inc (NASDAQ: EGRX) (before the market open) * Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) (after the close) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) (after the close) * 10X Genomics Inc (NASDAQ: TXG) (after the close) * Aimmune Therapeutics Inc (NASDAQ: AIMT) (after the close) * Acceleron Pharma Inc (NASDAQ: XLRN) (after the close) * Avadel Pharmaceuticals PLC (NASDAQ: AVDL) (after the close) * Pulse Biosciences Inc (NASDAQ: PLSE) (after the close) * Matinas BioPharma Holdings Inc (NYSE: MTNB) (after the close) * CorMedix Inc. (NYSE: CRMD) (after the close) * Castle Biosciences Inc (NASDAQ: CSTL) (after the close) * Omeros Corporation (NASDAQ: OMER) (after the close) * Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) (after the close) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) (after the close) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) (after the close) * Organogenesis Holdings Inc (NASDAQ: ORGO) (after the close) * Neos Therapeutics Inc (NASDAQ: NEOS) (after the close) * Retrophin In (NASDAQ: RTRX) (after the close) * Sangamo Therapeutics Inc (NASDAQ: SGMO) (after the close) * Rockwell Medical Inc (NASDAQ: RMTI) (after the close) * Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the close) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the close) * Misonix Inc (NASDAQ: MSON) (after the close) * Liquidia Technologies Inc (NASDAQ: LQDA) (after the close) * Cara Therapeutics Inc (NASDAQ: CARA) (after the close) * CymaBay Therapeutics Inc (NASDAQ: CBAY) (after the close) * ChemoCentryx Inc (NASDAQ: CCXI) (after the close) * DURECT Corporation (NASDAQ: DRRX) (after the close) * Endologix, Inc. (NASDAQ: ELGX) (after the close) * Exagen Inc (NASDAQ: XGN) (after the close) * Evolus Inc (NASDAQ: EOLS) (after the close) * Intersect ENT Inc (NASDAQ: XENT) (after the close) * Fate Therapeutics Inc (NASDAQ: FATE) (after the close)Tuesday * BioXcel Therapeutics Inc (NASDAQ: BTAI) (before the market open) * DarioHealth Corp (NASDAQ: DRIO) (before the market open) * Palatin Technologies, Inc. (NYSE: PT) (before the market open) * InspireMD Inc (NYSE: NSPR) (before the market open) * STRATA Skin Sciences Inc (NASDAQ: SSKN) (before the market open) * BioNTech SE - ADR (NASDAQ: BNTX) (before the market open) * aTyr Pharma Inc (NASDAQ: LIFE) (after the close) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) (after the close) * Gossamer Bio Inc (NASDAQ: GOSS) (after the close) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) (after the close) * Curis, Inc. (NASDAQ: CRIS) (after the close) * Clearpoint Neuro Inc (NASDAQ: CLPT) (after the close) * OncoCyte Corp (NYSE: OCX) (after the close) * Shockwave Medical Inc (NASDAQ: SWAV) (after the close) * Turning Point Therapeutics Inc (NASDAQ: TPTX) (after the close) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close) * TapImmune Inc. common stock (NASDAQ: MRKR) (after the close)Wednesday * PDS Biotechnology Corp (NASDAQ: PDSB) (before the market open) * Veru Inc (NASDAQ: VERU) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Applied Genetic Technologies Corp (NASDAQ: AGTC) (before the market open) * BioLife Solutions Inc (NASDAQ: BLFS) (after the close) * DiaMedica Therapeutics Inc (NASDAQ: DMAC) (after the close) * Viela Bio Inc (NASDAQ: VIE) (after the close) * Biocept Inc (NASDAQ: BIOC) (after the close) * Eyenovia Inc (NASDAQ: EYEN) (after the close) * Edap Tms SA (NASDAQ: EDAP) (after the close) * RA Medical Systems Inc (NYSE: RMED) (after the close) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) (after the close)Thursday * Vascular Biogenics Ltd (NASDAQ: VBLT) (before the market open) * ImmuCell Corporation (NASDAQ: ICCC) (before the market open) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open) * Transenterix Inc (NYSE: TRXC) (before the market open) * Adaptimmune Therapeutics PLC - ADR (NASDAQ: ADAP) (before the market open) * Aptinyx Inc (NASDAQ: APTX) (after the close) * Aytu Bioscience Inc (NASDAQ: AYTU) (after the close) * Applied DNA Sciences Inc (NASDAQ: APDN) (after the close) * INmune Bio Inc (NASDAQ: INMB) (after the close) * Dare Bioscience Inc (NASDAQ: DARE) (after the close) * Navidea Biopharmaceuticals Inc (NYSE: NAVB) (after the close) * Thermogenesis Holdings Inc (NASDAQ: THMO) (after the close) * Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close) * Onconova Therapeutics Inc (NASDAQ: ONTX) (after the close) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (after the close) * Viveve Medical Inc (NASDAQ: VIVE) (after the close) * Salarius Pharmaceuticals Inc (NASDAQ: SLRX) (after the close) * Vermillion, Inc. (NASDAQ: VRML) (after the close)Friday * Digirad Corporation (NASDAQ: DRAD) (before the market open) * Zyla Life Sciences (OTC: ZCOR) (before the market open) * PLx Pharma Inc (NASDAQ: PLXP) (before the market open)IPO Quiet Period Expiry ORIC Pharmaceuticals Inc (NASDAQ: ORIC)See more from Benzinga * 5 Biopharmas Where BofA Would Put Its Money To Work * The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda * The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged.Two-way Race The Watertown, Massachusetts-based company, which has a commercial antibiotic called Xerava to treat serious and life-threatening infections, is being pursued by La Jolla Pharmaceutical Company (NASDAQ: LJPC) after it signed a definitive agreement to be acquired by AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) in mid-March.La Jolla revealed in a filing it submitted a non-binding offer to acquire 100% of the equity of Tetraphase in an all-cash transaction.La Jolla offered for Tetraphase $22 million in cash, plus an additional $12.5 million potentially payable under contingent value rights, or CVRs, to be issued in the transaction.A contingent value right is a derivative instrument, with its value depending on some future event. If the event occurs by the specified date, then a holder of the CVR will get a pre-determined payout, mostly in cash."We are impressed with the growth potential of XERAVA and excited about the potential benefits of combining two companies focused on delivering important therapies to patients in the ICU," said Kevin Tang, Chairman of La Jolla in a letter addressed to the board of Tetraphase.Xerava, which was approved in August 2018, fetched Tetraphase revenues of $3.6 million in 2019 and $1.46 million in the fourth quarter of 2019.La Jolla said it plans to finance the proposed transaction with its cash on hand.Related Link: Attention Biotech Investors: Mark Your Calendar For These May PDUFA DatesAbout three weeks back, Tetraphase announced a definitive merger with AcelRx in a stock-for-stock transaction. The agreement provided for Tetraphase shareholders receiving 0.6303 share of AcelRx stock for each share they hold in Tetraphase, and a CVR, which will give the holders the right to receive aggregate payments of up to $12.5 million on achievement of future Xerava net sales milestones starting in 2021.The stock exchange ratio suggested valuation of $14.4 million at the close of trading March 13, a day before the deal was made public.AcelRx had said then it expects the deal to close in the second quarter. The boards of both companies vetted the transaction and certain stock and warrant holders holding an aggregate of approximately 31% of Tetraphase stock voting in favor of the deal.Merits Of The Offers La Jolla's superior cash offer cash might seem attractive at this juncture, as the world navigates through one of the worst crises it has ever faced."In our view, La Jolla's offer to Tetraphase hinges on an approximate $2.0M up-front premium to AcelRx's offer," H.C. Wainwright analyst Ed Arce said in a note. Despite La Jolla's higher consideration, he said Tetraphase might stick with the AcelRx offer.The terms of CVRs offered by both companies are same, except that La Jolla's CVRs would be paid in cash instead of cash or stock at the acquirer's option."We do not believe La Jolla's unsolicited competing bid is sufficiently compelling to Tetraphase to pull the company away from the current proposed transaction, especially given the amount of commitment and pre-close integration with AcelRx to date," Arce wrote in the note.The TTPH Move Tetraphase was up 89% to $2.63 at time of publication.Latest Ratings for TTPH DateFirmActionFromTo Mar 2020Gabelli & Co.DowngradesHoldSell Jan 2020Gabelli & Co.DowngradesBuyHold Oct 2019Gabelli & Co.UpgradesHoldBuy View More Analyst Ratings for TTPH View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AcelRx Pharmaceuticals (ACRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Monday, May 11, 2020. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 11, 2020 to discuss the financial results and provide an update on the company's business.
If you're interested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), then you might want to consider its beta (a...
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced that DSUVIA achieved Milestone C approval, a decision that clears the path for DSUVIA to be included in military sets, kits and outfits (SKOs).
Dark clouds are looming over Wall Street, and the storm only appears to be intensifying. The market was dealt another blow on Wednesday April 15, with all three of the major U.S. stock indexes sliding on grim economic data and disappointing earnings reports from banks.According to a Commerce Department report, March saw retail sales fall sharply, 8.7% to be exact. This marked the largest one-month drop since 1992, when the department began tracking the metric. Manufacturing in the New York area also declined by its largest margin ever, reaching a historic low to exceed levels witnessed during the Great Depression. Add in lackluster first quarter figures from Bank of America and Citigroup, and you have a recipe for heightened investor concern.Sure, the economic landscape appears gloomy, but if you look carefully, there’s a bright spot. COVID-19's worldwide rampage has slashed the price tags of some compelling names, providing attractive entry points.As a result, risk-tolerant investors have penny stocks on the mind. At under $5 per share, you get more bang for your buck and even minor share price appreciation can reflect huge percentage gains. However, due diligence is important here as Wall Street pros remind investors the bargain price could be a sign that a particular name faces overwhelming headwinds.Bearing this in mind, we used TipRanks’ database to pinpoint three Buy-rated penny stocks that have earned a thumbs up from members of the analyst community. Not to mention each boasts substantial upside potential of over 50%.AcelRx Pharmaceuticals (ACRX)AcelRx’s unique approach involves using a single-strength tablet in a distinct dosing unit to deliver drugs, which are designed to avoid the types of medication errors associated with injectable opioids. Shares have surged 53% in just the last month, but at $1.29 apiece, several analysts believe this stock is still undervalued.Writing for H.C. Wainwright, five-star analyst Ed Arce cites its Tetraphase Pharmaceuticals acquisition as a major positive. He argues that the deal could help ACRX establish a hospital-based commercial drug portfolio as Tetraphase’s only commercially available product, XERAVA, achieved Q4 sales of $1.5 million. As this result reflects a 49% sequential gain, Arce thinks “the drug is on a sustainable growth trajectory.”Arce doesn’t dispute the fact that there’s some concern surrounding Tetraphase’s financing risk and that its modest revenue and significant cost basis could signal a long path to profitability. “However, by combining DSUVIA and XERAVA net product sales under one streamlined cost structure, we believe the combined company may realize both revenue synergies (access to more areas across the hospital to promote both products) as well as more obvious cost synergies by removing duplication across operations, especially in sales and marketing,” he commented.Arce added, “Further, in addition to the acquisition which is expected to close in 2Q20 (see financial details below), the companies have agreed to enter a co-promotion arrangement effective immediately. As such, the companies plan to eliminate about 40 sales positions immediately (roughly half from each company), which provides an immediate cost savings of $8 million annually, before additional efficiency benefits from the acquisition itself.”To this end, Arce stayed with the bulls, reiterating a Buy recommendation. That being said, he did trim the price target from $9 to $7, but this still leaves room for 443% upside potential. (To watch Arce’s track record, click here)All in all, the rest of the Street is on the same page. Receiving 3 Buys and 1 Hold over the last three months, ACRX earns a Strong Buy consensus rating. At $1.29, the average price target implies shares could soar 381% in the next twelve months. (See AcelRx stock analysis on TipRanks).OPKO Health, Inc. (OPK)Hoping to address the unmet needs of patients, OPKO Health has developed innovative products, comprehensive diagnostics laboratories, a robust research and development pipeline and unique pharmaceutical business solutions to achieve this goal. With a price tag of $1.63 per share, analysts believe that now is the time to pull the trigger.Part of the excitement surrounding this healthcare name is related to the interim results of two clinical studies for its Rayaldee therapy. On March 25, OPK published data from a Phase 4 clinical trial evaluating Rayaldee compared to three other treatment regimens for secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and a Phase 2 clinical trial of Rayaldee for SHPT in adult patients with stage 5 CKD who need hemodialysis and have vitamin D insufficiency.The Phase 4 trial results were encouraging as they showed that at the given dose, the therapy could increase serum total 25-hydroxyvitamin D to the level required to effectively suppress elevated plasma intact parathyroid hormone (iPTH) in CKD patients. Not to mention the drug showed a robust safety profile.As for the Phase 2 trial, Laidlaw analyst Yale Jen noted, “The results so far achieved its initial goal of: 1) this level of drug is tolerable; 2) calcifediol, the active ingredient in Rayaldee can be activated in patients with absence of kidney function; and 3) SHPT can be treated in ESRD patients with this medication (>30% response rate).”The outcome is especially promising as it opens the door for Rayaldee’s use in end-stage renal disease (ESRD). “We are encouraged by the activation of calcifediol in ESRD patients possibly due to elevated activities of ex-renal enzyme as renal enzyme no longer functions. This could be an important discovery that might change the dogma of conventional understanding. The preliminary interim results of the Phase 2 in ESRD patients bode well, in our opinion, for the future second part of the Phase II study (n=300) given some of the key potential hurdles might have been removed,” Jen explained.Even though the company will need to discuss the Phase 2 data with the FDA and progress through the second part of the study before it can initiate pivotal trials in 2021 or 2022, Jen sees big things in store for OPK.As a result, the analyst left a Buy rating and $6 price target on this penny stock. Should the target be met, a twelve-month gain of 258% could be in the cards. (To watch Jen’s track record, click here)Turning now to the rest of the Street, other analysts have also been impressed with OPK. With 100% Street support, the consensus is unanimous: the stock is a Strong Buy. Additionally, the $4.33 average price target brings the upside potential to 158%. (See OPKO Health stock analysis on TipRanks)VEON Ltd. (VEON)Switching gears now, VEON offers connectivity and digital services to millions of people all over the world. Like the broader market, 2020 has been rough on this company, but with a $1.61 share price, there could be an opportunity for Wall Street observers to capitalize on its recent weakness.This is the stance taken by HSBC analyst Herve Drouet. He acknowledges that the company has faced significant headwinds related to both COVID-19 and recent weakness in many of its operating currencies. “The company issued a new trading update on 31 March 2020. The company expects COVID-19 led disruption to pose headwinds for roaming and equipment revenues. It also expects pressure on margins in Russia and Pakistan, while Ukraine is expected to continue its strong momentum,” he stated.As a result of these challenges, questions have been raised regarding its debt and ability to maintain its dividend payment. While the dividend is a concern for the analyst, he isn’t as alarmed by the debt situation.“However, in terms of its debt situation, we believe that the company should be able to refinance / meet its obligations using current cash and available credit lines. Furthermore, the company has capex flexibility – in case it is pushed to maximize cash flows for the short term. Any steps to rationalize its asset portfolio or improve margins in Russia should aid the stock,” Drouet commented.On top of this, VEON’s valuation is a key component of Drouet’s bullish thesis. “...on an EV/EBITDA basis appears to be trading at 3.3x 2020e EBITDA – below its 1yr forward average trading multiple of (3.6x) over the last five years and close to past trough levels on EV/OpCF basis (See page 5). Current valuations imply that the market is assuming a cost of equity of c17% for VEON (HSBCe:16%) or USD-RUB exchange rate of c88 vs current rate of c76. Any positive news like limited COVID-19 impact, oil price increase, or RUB appreciation should bode well for the stock, in our view,” the analyst noted.It should come as no surprise, then, that Drouet remains optimistic. Having said that, along with a Buy rating, he cut the price target from $3.10 to $1.80. (To watch Drouet’s track record, click here)All in all, VEON’s Moderate Buy consensus rating breaks down into 2 Buys and a single Hold. Based on its $2.43 average price target, the upside potential comes in at 50%. (See VEON analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Shareholders in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) had a terrible week, as shares crashed 22% to US$0.95 in...
NEW YORK, NY / ACCESSWIRE / March 17, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Tetraphase Pharmaceuticals, Inc. ("Tetraphase" ...
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Tetraphase Pharmaceuticals, Inc. ("TTPH" or the "Company") (NASDAQ: TTPH) in connection with the proposed acquisition of the Company by AcelRX Pharmaceuticals, Inc. ("ACRX") (NASDAQ: ACRX). Under the terms of the acquisition agreement, shareholders will receive 0.6303 shares of ACRX common stock for each share of TTPH they own. This represents consideration of $0.529 per TTPH share based on ACRX March 16 closing price.
WILMINGTON, DE / ACCESSWIRE / March 16, 2020 / Rigrodsky & Long, P.A. announces that it is investigating Tetraphase Pharmaceuticals, Inc. ("Tetraphase") (NASDAQ: TTPH ) regarding possible breaches ...
AcelRx Pharmaceuticals (NASDAQ:ACRX) reported Q4 results.Quarterly Results Earnings per share increased 100% over the past year to ($0.18), which beat the estimate of ($0.20).Revenue of $475,000 lower by 22.51% year over year, which missed the estimate of $1,010,000.Looking Ahead Q1 revenue expected between $2,300,000 and $2,300,000.Conference Call Details Date: Nov 06, 2019Time: 05:00 PM ETView more earnings on ACRXWebcast URL: https://www.webcaster4.com/Webcast/Page/406/32150Price Action Company's 52-week high was at $4.00Company's 52-week low was at $0.91Price action over last quarter: down 48.50%Company Overview AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.See more from Benzinga * Consolidated Water Co: Q4 Earnings Insights * Recap: New Age Beverages Q4 Earnings * Recap: Horizon Global Q4 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2019 financial results.